Biosimilars: Fact vs Fiction: Understanding biosimilars and their potential for lowering cancer care costs

Biosimilars are becoming quite the buzzword in cancer treatment, but cost, regulation, safety and efficacy are driving questions amongst payers and providers. In this webinar, NantHealth and a panel of respected medical experts examine:

  • The true definition of biosimilars and their potential in cancer care
  • The opportunities to drive down costs
  • Common misconceptions and concerns about safety and efficacy
  • Issues around payer reimbursement and provider incentives
  • The role of technology in navigating biosimilars

Panelists:

Sanjiv S. Agarwala HeadshotSanjiv S. Agarwala, MD
Chief of Medical Oncology at St. Luke’s Cancer Centre
&
Professor of Medicine at Temple University School of Medicine
William Flood HeadshotWilliam Flood, MD
Chief Medical Officer
Eviti, NantHealth
E. Paul Amundson HeadshotE. Paul Amundson, MD, FAAFP
Medical Director, Medical Affairs
CVS Caremark